Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Background to Gilead's $21 Bln acquisition of Immunomedics

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Nov 21, 2021 5:41pm

253 Views

Post# 34151146

RE:RE:RE:RE:RE:Background to Gilead's $21 Bln acquisition of Immunomedics

also I have been told many times in the past to not rely on clinical trials.gov for updates as they are usually 2-3 months behind or more on the proper updates, this info from when onc used to talk to shareholders.

<< Previous

Bullboard Posts

Next >>

Three micro-cap value stocks trading at peak pessimism